Over the past 20 years, significant improvements have been made in NSCLC treatment with the advent of targeted therapies [3, 4, 5, 6] for genetic alterations, including but not limited to epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements [7]. Here, ALK is linked to non-small cell lung carcinoma.